Acute diarrhea following the first subcutaneous dose of tafolecimab: a case report of a probable adverse drug reaction
Abstract
BackgroundTafolecimab is a fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Diarrhea is a recognized adverse reaction, but detailed post-marketing case descriptions with clear timing, differential assessment, and outcome remain limited.Case SummaryA 51-year-old man hospitalized for non-ST-segment elevation myocardial infarction received his first one-time 600-mg subcutaneous dose of tafolecimab (SINTBILO) at 15:14 on 13 July 2026. Approximately 7 h 46 min later, he developed abdominal pain and diarrhea occurring 5–8 times daily, with nausea and mild periumbilical pain but no fever, tenesmus, visible hematochezia or melena, dehydration, hypotension, rebound tenderness, or guarding. Stool testing showed loose yellow stool, positive occult blood and red blood cells, 0–1 white blood cells/high-power field, and a negative rotavirus test; electrolytes and liver and kidney function were normal. Stool culture and testing for Clostridioides difficile, norovirus, and adenovirus were not performed. Tafolecimab was not re-administered. After fluid replacement, montmorillonite, and loperamide hydrochloride, diarrhea decreased within 1 day and resolved after approximately 2 days, with no recurrence after discharge. Long-term stable acarbose therapy was continued without recurrence. The Naranjo score was 5, indicating a probable adverse drug reaction.ConclusionThis case supports probable tafolecimab-associated acute diarrhea. New-onset diarrhea after PCSK9 inhibitor initiation should prompt precise temporal documentation, medication reconciliation, targeted microbiological evaluation, and pharmacovigilance reporting.
Related
- Probable isolated ocular surface blood transfusion reaction in a patient with advanced prostate cancer: a case report
- Peritonitis following subcutaneous embedding of peritoneal dialysis catheters at PD discontinuation: two cases within a six-patient institutional series and a literature review
- Erythroderma Following Fluphenazine Decanoate Injection: A Rare Adverse Drug Reaction in a Resource‐Limited Setting
- Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report.
- Delayed Histiocytic Foreign Body Reaction and Granuloma Formation Following Argiform Injection for Soft Tissue Augmentation Mimicking a Lipomatous Tumor on Histopathology: A Case Report.
BibTeX
@article{he2026acute,
title = {{Acute diarrhea following the first subcutaneous dose of tafolecimab: a case report of a probable adverse drug reaction}},
author = {Jie He},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1941709},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1941709},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Acute diarrhea following the first subcutaneous dose of tafolecimab: a case report of a probable adverse drug reaction
AU - Jie He
PY - 2026
DA - 2026/11/13
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1941709
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1941709
AB - BackgroundTafolecimab is a fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Diarrhea is a recognized adverse reaction, but detailed post-marketing case descriptions with clear timing, differential assessment, and outcome remain limited.Case SummaryA 51-year-old man hospitalized for non-ST-segment elevation myocardial infarction received his first one-time 600-mg subcutaneous dose of tafolecimab (SINTBILO) at 15:14 on 13 July 2026. Approximately 7 h 46 min later, he developed abdominal pain and diarrhea occurring 5–8 times daily, with nausea and mild periumbilical pain but no fever, tenesmus, visible hematochezia or melena, dehydration, hypotension, rebound tenderness, or guarding. Stool testing showed loose yellow stool, positive occult blood and red blood cells, 0–1 white blood cells/high-power field, and a negative rotavirus test; electrolytes and liver and kidney function were normal. Stool culture and testing for Clostridioides difficile, norovirus, and adenovirus were not performed. Tafolecimab was not re-administered. After fluid replacement, montmorillonite, and loperamide hydrochloride, diarrhea decreased within 1 day and resolved after approximately 2 days, with no recurrence after discharge. Long-term stable acarbose therapy was continued without recurrence. The Naranjo score was 5, indicating a probable adverse drug reaction.ConclusionThis case supports probable tafolecimab-associated acute diarrhea. New-onset diarrhea after PCSK9 inhibitor initiation should prompt precise temporal documentation, medication reconciliation, targeted microbiological evaluation, and pharmacovigilance reporting.
SN - 1663-9812
ER -